Germán E Sánchez-Morales, Jorge L Osorio-Serrano, Alan Guerrero-Gómez, Carlos Chan, Ismael Domínguez-Rosado
{"title":"[Surgical resection and survival of clear cell renal cancer metastases to the pancreas].","authors":"Germán E Sánchez-Morales, Jorge L Osorio-Serrano, Alan Guerrero-Gómez, Carlos Chan, Ismael Domínguez-Rosado","doi":"10.24875/CIRU.22000379","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Pancreas is considered one of the organs most frequently affected by recurrence after nephrectomy secondary to renal cell carcinoma reporting an incidence of 20%, 85% of these occur within the first 3 years.</p><p><strong>Objective: </strong>The objective of the study is to evaluate overall survival and disease-free survival in patients with renal cancer and pancreatic metastases who underwent surgical treatment.</p><p><strong>Methods: </strong>A retrospective cross-sectional study of patients with histological diagnosis of renal cancer associated with pancreatic metastasis was performed and included those treated by pancreatoduodenectomy or distal pancreatectomy during the period 1987-2020.</p><p><strong>Results: </strong>14 patients with pancreatic metastasis were included. Two groups of patients were obtained: those who underwent pancreatic surgery for metastasis and those who did not undergo surgical procedure. According to the location of the metastasis, 71.4% corresponded to a single location and 28.6% to multiple locations. 57.1% underwent Whipple and 42.9% distal pancreatectomy. Survival after the surgical procedure was 1150 days versus 499 days in non-operated patients.</p><p><strong>Conclusion: </strong>Pancreatic metastases due to RCC can be curable, improve morbidity, and increase disease-free survival with surgical treatment.</p>","PeriodicalId":93936,"journal":{"name":"Cirugia y cirujanos","volume":" ","pages":"451-455"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cirugia y cirujanos","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24875/CIRU.22000379","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Pancreas is considered one of the organs most frequently affected by recurrence after nephrectomy secondary to renal cell carcinoma reporting an incidence of 20%, 85% of these occur within the first 3 years.
Objective: The objective of the study is to evaluate overall survival and disease-free survival in patients with renal cancer and pancreatic metastases who underwent surgical treatment.
Methods: A retrospective cross-sectional study of patients with histological diagnosis of renal cancer associated with pancreatic metastasis was performed and included those treated by pancreatoduodenectomy or distal pancreatectomy during the period 1987-2020.
Results: 14 patients with pancreatic metastasis were included. Two groups of patients were obtained: those who underwent pancreatic surgery for metastasis and those who did not undergo surgical procedure. According to the location of the metastasis, 71.4% corresponded to a single location and 28.6% to multiple locations. 57.1% underwent Whipple and 42.9% distal pancreatectomy. Survival after the surgical procedure was 1150 days versus 499 days in non-operated patients.
Conclusion: Pancreatic metastases due to RCC can be curable, improve morbidity, and increase disease-free survival with surgical treatment.